Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin in Bacterial Pneumonia and Chronic Respiratory Disease Infections
NCT01561794Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2012
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ciprofloxacin in pneumonia and Chronic Respiratory Disease (CRD), sponsored by Bayer. Primary endpoints: Safety variables based on adverse events collection, Area under the blood concentration/time curve and 5 more. Started May 2012; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
pneumoniaChronic Respiratory Disease (CRD)
Beyond the preview
Go deeper on NCT01561794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561794.